Newsroom
23 press releases and 54 media coverage stories
Clinical Trials Arena: Promising Future for AI in Cell Therapy
Clinical Trials Arena
Technology is transforming healthcare, with a major focus on the development of precision medicine. Josh Ludwig, Global Director of ScaleReady, discusses the implications of automation and AI in cell therapy.
Read the article : Clinical Trials Arena: Promising Future for AI in Cell TherapyShare: Clinical Trials Arena: Promising Future for AI in Cell Therapy
The Medicine Maker: Industry 4.0 and Advanced Manufacturing
The Medicine Maker
The Medicine Maker gathered four experts, including ScaleReady's Josh Ludwig, to discuss what’s changed, what’s changing, and what the future looks like for Industry 4.0 in pharma manufacturing, knowing the industry traditionally lags somewhat in this uptake.
Read the article : The Medicine Maker: Industry 4.0 and Advanced ManufacturingShare: The Medicine Maker: Industry 4.0 and Advanced Manufacturing
InViVo Citeline Commerical: Women in advanced therapies: How diverse is the sector really?
InViVo Citeline Commerical
Cell and gene therapy is a young biopharma sector approaching adolescence. As more companies transition from R&D to commercialization, has it got the balance right on diversity in senior leadership?
Read the article : InViVo Citeline Commerical: Women in advanced therapies: How diverse is the sector really?Share: InViVo Citeline Commerical: Women in advanced therapies: How diverse is the sector really?
pharmaphorum: Standardizing Workflows to Improve Efficiency
pharmaphorum
While innovation drove the early stages of cell therapy development, the industry is now transitioning to address the challenges of delivering these therapies to patients on a large scale. Josh Ludwig of ScaleReady emphasizes the importance of standardized workflows that are scalable and easily automated to improve efficiency.
Read the article : pharmaphorum: Standardizing Workflows to Improve EfficiencyShare: pharmaphorum: Standardizing Workflows to Improve Efficiency
CTMC partners with ScaleReady to automate, close, and scale for greater patient accessibility
PharmiWeb
The agreement will enable CTMC to strategically scale the recently completed GMP facility to drive high-throughput manufacturing utilizing the automated, closed system capabilities of the Fresenius Kabi Lovo® and Cue® cell processing systems.
Read the release : CTMC partners with ScaleReady to automate, close, and scale for greater patient accessibilityShare: CTMC partners with ScaleReady to automate, close, and scale for greater patient accessibility
BioProcess International: Prioritize Simplifying Processes Over Automating
BioProcess International
Automation is necessary for the future of CGT manufacturing to reduce contamination risk. However, as Jenny Stjernberg of ScaleReady highlights in this BioProcess International article, premature automation without simplifying processes can lead to longer timelines, increased risk, and financial strain.
Read the article : BioProcess International: Prioritize Simplifying Processes Over AutomatingShare: BioProcess International: Prioritize Simplifying Processes Over Automating
Drug Discovery World: Advanced Therapies Europe: From bench to bedside and boardroom
Drug Discovery World
Drug Discovery World asked Advanced Therapies Europe attendees: What is most important to scale from discovery to commercialization of cell and gene therapies (CGTs)? ScaleReady’s Josh Ludwig answers.
Read the article : Drug Discovery World: Advanced Therapies Europe: From bench to bedside and boardroomShare: Drug Discovery World: Advanced Therapies Europe: From bench to bedside and boardroom
Pharma’s Almanac: Leveraging Real-word Data in Cell and Gene Therapy
Pharma's Almanac
Cell therapies show remarkable potential in treating challenging lymphomas, as demonstrated by real-world data. But companies may run out of funds before reaching milestones due to factors like inefficient manufacturing, facility costs, and difficulties scaling processes. Alaina Schlinker, Ph.D., Senior Manager, Field Applications Support, ScaleReady, discusses how ScaleReady's platforms aim to help developers reach clinical milestones quickly and cost-effectively.
Read the article : Pharma’s Almanac: Leveraging Real-word Data in Cell and Gene TherapyShare: Pharma’s Almanac: Leveraging Real-word Data in Cell and Gene Therapy
Pharma’s Almanac: What Conventional Industry Wisdom is Misguided, Outdated, or Wrong?
Pharma's Almanac
Industry experts, including Jenny Stjernberg, Ph.D., Commercial Director, EMEA, discuss which conventional industry wisdom they believe is misguided, outdated, or just plain wrong with Pharma's Almanac. Jenny discusses how many developers have too-literally retained the conventional wisdom that for cell-based therapies "process is product."
Read the article : Pharma’s Almanac: What Conventional Industry Wisdom is Misguided, Outdated, or Wrong?Share: Pharma’s Almanac: What Conventional Industry Wisdom is Misguided, Outdated, or Wrong?
RegMedNet Interview: Preserving flexibility and the significance of cryopreservation in every step of the cell and gene therapy workflow
RegMedNet
In an exclusive interview with RegMedNet, Jenny Stjernberg discusses the crucial role of scalability in advancing groundbreaking therapies. Stjernberg emphasizes the importance of preserving flexibility while scaling up cell therapy manufacturing approaches.
Read the article : RegMedNet Interview: Preserving flexibility and the significance of cryopreservation in every step of the cell and gene therapy workflowShare: RegMedNet Interview: Preserving flexibility and the significance of cryopreservation in every step of the cell and gene therapy workflow
RegMedNet: Standardizing Cell Therapy Processes
RegMedNet
In this interview, Josh Ludwig talks about the importance of collaboration and standardization in developing and manufacturing cell therapies. Josh explains how standardizing processes across the industry can be achieved by…
Read the article : RegMedNet: Standardizing Cell Therapy ProcessesShare: RegMedNet: Standardizing Cell Therapy Processes
The Medicine Maker: Roundtable Discussion — Redefining Manufacturing
The Medicine Maker
Watch the roundtable discussion from Medicine Maker featuring experts from ScaleReady, Terumo Blood and Cell Technologies, Orgenesis, and BioBridge Global.
Read the article : The Medicine Maker: Roundtable Discussion — Redefining ManufacturingShare: The Medicine Maker: Roundtable Discussion — Redefining Manufacturing
